Clinical Trial Update: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update for Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) has been terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Snippet

Sponsor: University of California, San Francisco | Conditions: Ischemic Attack, Transient | Phase 3 | Status: TERMINATED | Results posted: 2018-12-04